Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.
actionable ideas
biomarkers
genomic differences
immunotherapy
molecular differences
racial disparity
socioeconomic issues
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
22
11
2020
received:
26
05
2020
accepted:
02
12
2020
pubmed:
19
2
2021
medline:
8
3
2022
entrez:
18
2
2021
Statut:
ppublish
Résumé
African Americans (AAs) in the United States are known to have a higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological disparity are multifactorial, including socioeconomic factors leading to lifestyle and dietary issues, healthcare access problems, and potentially tumor biology. Although recent evidence suggests once access is equal, AA men have equal outcomes to Caucasian American (CA) men, differences in PCa incidence remain, and there is much to do to reverse disparities in mortality across the USA. A deeper understanding of these issues, both at the clinical and molecular level, can facilitate improved outcomes in the AA population. This review first discusses PCa oncogenesis in the context of its diverse hallmarks before benchmarking key molecular and genomic differences for PCa in AA men that have emerged in the recent literature. Studies have emphasized the importance of tumor microenvironment that contributes to both the unequal cancer burden and differences in clinical outcome between the races. Management of comorbidities like obesity, hypertension, and diabetes will provide an essential means of reducing prostate cancer incidence in AA men. Although requiring further AA specific research, several new treatment strategies such as immune checkpoint inhibitors used in combination PARP inhibitors and other emerging vaccines, including Sipuleucel-T, have demonstrated some proven efficacy. Genomic profiling to integrate clinical and genomic data for diagnosis, prognosis, and treatment will allow physicians to plan a "Precision Medicine" approach to AA men. There is a pressing need for further research for risk stratification, which may allow early identification of AA men with higher risk disease based on their unique clinical, genomic, and immunological profiles, which can then be mapped to appropriate clinical trials. Treatment options are outlined, with a concise description of recent work in AA specific populations, detailing several targeted therapies, including immunotherapy. Also, a summary of current clinical trials involving AA men is presented, and it is important that policies are adopted to ensure that AA men are actively recruited. Although it is encouraging that many of these explore the lifestyle and educational initiatives and therapeutic interventions, there is much still work to be done to reduce incidence and mortality in AA men and equalize current racial disparities.
Sections du résumé
BACKGROUND
African Americans (AAs) in the United States are known to have a higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological disparity are multifactorial, including socioeconomic factors leading to lifestyle and dietary issues, healthcare access problems, and potentially tumor biology.
RECENT FINDINGS
Although recent evidence suggests once access is equal, AA men have equal outcomes to Caucasian American (CA) men, differences in PCa incidence remain, and there is much to do to reverse disparities in mortality across the USA. A deeper understanding of these issues, both at the clinical and molecular level, can facilitate improved outcomes in the AA population. This review first discusses PCa oncogenesis in the context of its diverse hallmarks before benchmarking key molecular and genomic differences for PCa in AA men that have emerged in the recent literature. Studies have emphasized the importance of tumor microenvironment that contributes to both the unequal cancer burden and differences in clinical outcome between the races. Management of comorbidities like obesity, hypertension, and diabetes will provide an essential means of reducing prostate cancer incidence in AA men. Although requiring further AA specific research, several new treatment strategies such as immune checkpoint inhibitors used in combination PARP inhibitors and other emerging vaccines, including Sipuleucel-T, have demonstrated some proven efficacy.
CONCLUSION
Genomic profiling to integrate clinical and genomic data for diagnosis, prognosis, and treatment will allow physicians to plan a "Precision Medicine" approach to AA men. There is a pressing need for further research for risk stratification, which may allow early identification of AA men with higher risk disease based on their unique clinical, genomic, and immunological profiles, which can then be mapped to appropriate clinical trials. Treatment options are outlined, with a concise description of recent work in AA specific populations, detailing several targeted therapies, including immunotherapy. Also, a summary of current clinical trials involving AA men is presented, and it is important that policies are adopted to ensure that AA men are actively recruited. Although it is encouraging that many of these explore the lifestyle and educational initiatives and therapeutic interventions, there is much still work to be done to reduce incidence and mortality in AA men and equalize current racial disparities.
Identifiants
pubmed: 33599076
doi: 10.1002/cnr2.1340
pmc: PMC8551995
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1340Subventions
Organisme : Deane Prostate Health, ISMMS
Organisme : The Arthur M. Blank Family Foundation
Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Expert Rev Clin Pharmacol. 2017 Aug;10(8):889-898
pubmed: 28573914
PLoS One. 2018 Sep 11;13(9):e0203322
pubmed: 30204798
J Clin Endocrinol Metab. 1996 Dec;81(12):4400-5
pubmed: 8954049
Cancer. 2005 Sep 1;104(5):962-7
pubmed: 16007688
PLoS One. 2018 Sep 10;13(9):e0203855
pubmed: 30199553
Pharmacogenetics. 2000 Jul;10(5):373-88
pubmed: 10898107
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Br J Cancer. 2015 Jul 14;113(2):193-8
pubmed: 26125442
Annu Rev Physiol. 1998;60:575-600
pubmed: 9558477
PLoS One. 2010 May 10;5(5):e10547
pubmed: 20479932
Cancer Lett. 2004 Apr 30;207(2):131-7
pubmed: 15151133
J Clin Invest. 2013 Mar;123(3):1109-22
pubmed: 23426182
Cancer Res. 2000 Oct 15;60(20):5710-3
pubmed: 11059764
Trans Am Clin Climatol Assoc. 2000;111:271-92; discussion 292-3
pubmed: 10881346
Cancer Res. 2000 Oct 1;60(19):5334-9
pubmed: 11034066
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Eur Urol. 2016 Jul;70(1):14-17
pubmed: 26443432
Eur Urol. 2017 May;71(5):740-747
pubmed: 27989354
Nucleic Acids Res. 2000 Feb 1;28(3):669-77
pubmed: 10637317
Br J Cancer. 2004 Aug 16;91(4):783-7
pubmed: 15280931
Endocrinology. 2005 Feb;146(2):950-9
pubmed: 15539552
BJU Int. 2005 Dec;96(9):1247-52
pubmed: 16287439
Technol Cancer Res Treat. 2017 Apr;16(2):159-166
pubmed: 28279145
Nephrourol Mon. 2013 Jul 1;5(3):792-800
pubmed: 24282788
Mol Cell Pharmacol. 2010;2(5):213-219
pubmed: 21289871
Gene. 2018 May 15;654:36-42
pubmed: 29452232
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Clin Cancer Res. 2014 Sep 15;20(18):4925-34
pubmed: 25056375
Prostate. 2011 Apr;71(5):489-97
pubmed: 20878952
Nat Genet. 2009 May;41(5):619-24
pubmed: 19396168
Arch Biochem Biophys. 1991 Oct;290(1):160-6
pubmed: 1898086
Genomics. 2019 Jan;111(1):10-16
pubmed: 26902887
Methods Mol Biol. 2009;471:291-303
pubmed: 19109786
Cancer Res. 2008 Feb 1;68(3):927-36
pubmed: 18245496
Cancer Res. 2014 May 15;74(10):2763-72
pubmed: 24686169
Front Biosci (Landmark Ed). 2017 Jan 1;22:772-782
pubmed: 27814645
Mol Cancer Ther. 2016 Aug;15(8):1781-91
pubmed: 27413114
Nat Genet. 2007 May;39(5):638-44
pubmed: 17401364
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14477-82
pubmed: 16973750
Br J Cancer. 2016 May 10;114(10):1090-100
pubmed: 27115471
Clin Cancer Res. 2016 Apr 1;22(7):1744-56
pubmed: 26553749
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Scientifica (Cairo). 2012;2012:701810
pubmed: 24124627
Prostate Cancer. 2013;2013:763569
pubmed: 23365759
J Transl Med. 2010 Jul 22;8:70
pubmed: 20649978
Oncologist. 2019 Apr;24(4):444-448
pubmed: 30541755
Nature. 2010 Jun 24;465(7301):1033-8
pubmed: 20577206
J Urol. 2004 Apr;171(4):1513-9
pubmed: 15017210
Genome Res. 2007 Dec;17(12):1717-22
pubmed: 17978284
Cancer Res. 1998 Jan 15;58(2):204-9
pubmed: 9443392
Hum Mol Genet. 1997 Nov;6(12):2011-9
pubmed: 9328464
Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):379-84
pubmed: 9610786
Cancer Cell. 2020 May 11;37(5):639-654.e6
pubmed: 32396860
J Natl Cancer Inst. 1986 Jan;76(1):45-8
pubmed: 3455741
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
J Steroid Biochem Mol Biol. 2017 Feb;166:1-15
pubmed: 27117390
Nat Genet. 2009 May;41(5):524-6
pubmed: 19396167
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
Eur Urol. 2009 Aug;56(2):275-86
pubmed: 19409690
Cancer Lett. 2018 Feb 1;414:153-165
pubmed: 29154974
Cell. 2004 Nov 24;119(5):591-602
pubmed: 15550242
Br J Cancer. 2011 Aug 9;105(4):481-5
pubmed: 21829203
Neoplasia. 2014 Nov 20;16(11):900-8
pubmed: 25425964
Apoptosis. 2009 Apr;14(4):584-96
pubmed: 19156528
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Clin Cancer Res. 2012 May 15;18(10):2882-95
pubmed: 22589488
J Urol. 2004 Nov;172(5 Pt 1):1848-52
pubmed: 15540736
Ther Adv Hematol. 2018 Aug 27;9(9):273-293
pubmed: 30210756
J Urol. 2016 Nov;196(5):1436-1444
pubmed: 27238617
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Mod Pathol. 2010 Oct;23(10):1325-33
pubmed: 20562851
J Urol. 2014 Jan;191(1):60-7
pubmed: 23770146
Prostate. 2013 Jan;73(1):11-22
pubmed: 22549899
Mol Cell Proteomics. 2016 Dec;15(12):3564-3580
pubmed: 27742740
Cancer Res. 2016 Apr 1;76(7):1860-8
pubmed: 26921337
Cancer Res. 2017 Jan 1;77(1):74-85
pubmed: 27793843
J Clin Oncol. 2015 Sep 1;33(25):2789-96
pubmed: 26195723
Adv Drug Deliv Rev. 2014 Jun;73:162-9
pubmed: 24583376
Am J Hum Genet. 2003 Jan;72(1):1-12
pubmed: 12474142
Eur Urol. 2019 Jan;75(1):11-15
pubmed: 30245085
Cancer Rep (Hoboken). 2021 Oct;4(5):e1340
pubmed: 33599076
Nat Med. 2010 Mar;16(3):286-94
pubmed: 20154697
Int J Cancer. 2000 Aug 1;87(3):434-7
pubmed: 10897051
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Eur Urol. 2004 Dec;46(6):698-708
pubmed: 15548435
Cancer Res. 2017 Aug 15;77(16):4247-4257
pubmed: 28611045
Prostate. 2005 Jul 1;64(2):160-7
pubmed: 15678501
Oncotarget. 2017 May 23;8(34):56698-56713
pubmed: 28915623
J Clin Oncol. 2002 Sep 1;20(17):3599-604
pubmed: 12202660
CA Cancer J Clin. 2016 Jul;66(4):290-308
pubmed: 26910411
Oncotarget. 2017 Jan 31;8(5):8356-8368
pubmed: 28039468
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Clin Cancer Res. 1998 Mar;4(3):811-5
pubmed: 9533551
Mol Cell Biol. 2007 Nov;27(21):7538-50
pubmed: 17709381
Mol Cancer. 2006 Jul 18;5:28
pubmed: 16848908
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229666
Nucleic Acids Res. 1994 Aug 11;22(15):3181-6
pubmed: 8065934
Cancer. 2020 Apr 15;126(8):1683-1690
pubmed: 31984482
Urol Oncol. 2006 Jan-Feb;24(1):21-7
pubmed: 16414488
Protein Cell. 2013 May;4(5):331-41
pubmed: 23636686
Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):25-30
pubmed: 28315704
Urology. 2006 Aug;68(2):337-41
pubmed: 16904448
Cancer Res. 1993 Jul 15;53(14):3369-73
pubmed: 8324747
Thromb Haemost. 2005 May;93(5):964-75
pubmed: 15886816
Am J Surg Pathol. 2007 Jun;31(6):882-8
pubmed: 17527075
Oncogene. 1998 Apr 2;16(13):1743-8
pubmed: 9582022
Mod Pathol. 2018 Oct;31(10):1539-1552
pubmed: 29849114
Cancers (Basel). 2018 Aug 24;10(9):
pubmed: 30149591
Cancer Lett. 2014 Jun 1;347(2):167-74
pubmed: 24561061
J Clin Oncol. 2005 Jan 20;23(3):455-60
pubmed: 15659491
Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):943-7
pubmed: 11535545
PLoS One. 2011 Jan 06;6(1):e14495
pubmed: 21253579
Int J Cancer. 2000 Mar 20;89(2):172-6
pubmed: 10754496
Front Immunol. 2019 Mar 28;10:603
pubmed: 30984182
Nat Biotechnol. 2011 Jul 31;29(8):742-9
pubmed: 21804560
Cancer Res. 1995 Sep 15;55(18):3973-5
pubmed: 7664265
Biomark Res. 2018 Mar 9;6:10
pubmed: 29556394
Front Immunol. 2018 Apr 18;9:813
pubmed: 29720980
Cell Immunol. 2014 Jul;290(1):120-30
pubmed: 24978612
Cancer Res. 2018 Dec 15;78(24):6736-6746
pubmed: 30217929
Sci Transl Med. 2011 Mar 2;3(72):72ra17
pubmed: 21368222
J Clin Oncol. 2010 Sep 1;28(25):3958-64
pubmed: 20679621
Cancer Lett. 2004 Mar 18;205(2):181-8
pubmed: 15036650
Cancer Cell. 2008 Jun;13(6):519-28
pubmed: 18538735
Ann Oncol. 2009 Mar;20(3):550-5
pubmed: 18765462
Nat Genet. 1999 Feb;21(2):220-4
pubmed: 9988278
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Oncol Lett. 2018 Dec;16(6):6895-6902
pubmed: 30546421
Hum Mol Genet. 2010 Feb 15;19(4):720-30
pubmed: 19942621
Clin Cancer Res. 2010 Feb 15;16(4):1094-9
pubmed: 20145169
Sci Rep. 2018 Nov 5;8(1):16335
pubmed: 30397274
Nat Rev Urol. 2017 Oct;14(10):607-619
pubmed: 28675175
Oncotarget. 2014 Jun 15;5(11):3512-25
pubmed: 25004396
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Urol. 2011 Dec;186(6):2233-7
pubmed: 22019035
Pharmacogenetics. 1999 Oct;9(5):635-9
pubmed: 10591544
Prostate Cancer Prostatic Dis. 2011 Sep;14(3):262-5
pubmed: 21519348
Nat Commun. 2017 Oct 20;8(1):1081
pubmed: 29057879
Pharmacogenomics. 2017 May;18(7):597-600
pubmed: 28468521
Nature. 2011 Apr 7;472(7341):120-4
pubmed: 21423168
Oncogene. 2008 Sep 11;27(40):5348-53
pubmed: 18542058
Cancer Res. 2018 Nov 1;78(21):6134-6145
pubmed: 30181178
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):419-428
pubmed: 31844180
Cancer Res. 2012 Feb 1;72(3):616-25
pubmed: 22158653
Prostate. 2019 Feb;79(2):215-222
pubmed: 30345534
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1374-1380
pubmed: 32503813
J Urol. 1994 Feb;151(2):492-5
pubmed: 7904314
J Urol. 2009 Oct;182(4):1621-7
pubmed: 19683746
Oncotarget. 2018 Jan 9;9(10):9206-9218
pubmed: 29507684
J Urol. 2013 Jul;190(1):317-24
pubmed: 23376149
Clin Cancer Res. 2015 Nov 1;21(21):4970-84
pubmed: 26089375
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1021-5
pubmed: 16702386
Am J Pathol. 1998 Jul;153(1):141-8
pubmed: 9665474
Community Dent Oral Epidemiol. 2004 Oct;32(5):363-73
pubmed: 15341621
Eur Urol. 2014 Dec;66(6):978-81
pubmed: 25015038
Cell Biochem Biophys. 2015 Mar;71(2):983-91
pubmed: 25323563
Clin Cancer Res. 1999 Aug;5(8):2082-8
pubmed: 10473090
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Nat Rev Cancer. 2007 Feb;7(2):139-47
pubmed: 17218951
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80
pubmed: 10491435
J Med Genet. 2006 Jun;43(6):507-11
pubmed: 16155194
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Cancer Res. 2001 Sep 1;61(17):6532-9
pubmed: 11522651
Cancer Manag Res. 2012;4:183-93
pubmed: 22904640
Clin Cancer Res. 2007 Jul 15;13(14):4130-8
pubmed: 17634540
EMBO J. 2002 Aug 1;21(15):4037-48
pubmed: 12145204
Cancer Lett. 2010 May 1;291(1):1-13
pubmed: 19717225
Hum Genet. 2009 Nov;126(5):637-42
pubmed: 19568772
J Natl Cancer Inst. 2016 Jan 27;108(7):
pubmed: 26823525
Cancer. 2005 Feb 1;103(3):528-37
pubmed: 15630701
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Oncol Lett. 2017 Apr;13(4):2483-2489
pubmed: 28454424
Nature. 2011 Feb 10;470(7333):214-20
pubmed: 21307934
Prostate. 2013 May;73(6):614-23
pubmed: 23060098
PLoS One. 2014 Nov 19;9(11):e113190
pubmed: 25409505
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
Oncotarget. 2014 Sep 15;5(17):7217-59
pubmed: 25277175
Eur J Med Chem. 2016 Feb 15;109:314-41
pubmed: 26807863
Trends Cancer. 2020 Nov;6(11):974-984
pubmed: 32517958
Asian J Androl. 2012 Sep;14(5):726-31
pubmed: 22902907
Cancer Res. 2004 Mar 15;64(6):1975-86
pubmed: 15026333
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Prev Med. 2003 Jun;36(6):721-30
pubmed: 12744916
Cancer Lett. 2019 Feb 28;443:80-90
pubmed: 30472184
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24
pubmed: 15647368
Am J Clin Exp Urol. 2017 Nov 09;5(3):34-48
pubmed: 29181436
Cancers (Basel). 2013 May 24;5(2):569-90
pubmed: 24216992
J Clin Pathol. 2005 Jul;58(7):673-84
pubmed: 15976331
Cancer Cell. 2011 Aug 16;20(2):173-86
pubmed: 21840483
Urology. 2009 Mar;73(3):624-30
pubmed: 19167034
Cancer Res. 2004 Apr 1;64(7):2619-26
pubmed: 15059919
J Urol. 1998 Jun;159(6):1979-82; discussion 1982-3
pubmed: 9598502
JAMA Oncol. 2019 Jul 1;5(7):975-983
pubmed: 31120534
Oncotarget. 2016 Dec 13;7(50):82504-82510
pubmed: 27756888
Genes Dev. 2010 Sep 15;24(18):1967-2000
pubmed: 20844012
Oncoscience. 2016 Mar 03;3(2):54-5
pubmed: 27014722
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
Prostate. 2013 May;73(6):668-76
pubmed: 23129512
DNA. 1987 Oct;6(5):439-48
pubmed: 3500022
Biosci Biotechnol Biochem. 2017 Dec;81(12):2301-2306
pubmed: 29050519
Am J Transl Res. 2009 Apr 20;1(3):235-48
pubmed: 19956434
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Oncotarget. 2016 May 31;7(22):31825-31
pubmed: 26025918
Cell Physiol Biochem. 2018;48(1):149-157
pubmed: 30001553
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73
pubmed: 16945910
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Curr Drug Targets. 2016;17(3):311-20
pubmed: 26343112
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769418
Clin Cancer Res. 2010 Jul 15;16(14):3539-47
pubmed: 20606036
J Natl Cancer Inst. 1997 Jan 15;89(2):158-65
pubmed: 8998185
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Science. 2014 Oct 3;346(6205):85-89
pubmed: 25278611
J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90
pubmed: 24292212
Carcinogenesis. 2018 Dec 13;39(11):1311-1319
pubmed: 30304372
Mol Cancer. 2007 Jun 06;6:39
pubmed: 17553165
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320-3
pubmed: 9096391
Br J Biomed Sci. 2011;68(3):138-42
pubmed: 21950206
Nat Rev Urol. 2016 Feb;13(2):99-107
pubmed: 26718455
Curr Opin Urol. 2016 May;26(3):231-9
pubmed: 26909474
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
APMIS. 2012 Nov;120(11):901-8
pubmed: 23009114
PLoS One. 2012;7(2):e31226
pubmed: 22359577
J Urol. 2003 Sep;170(3):990-3
pubmed: 12913756
Nat Genet. 2013 Nov;45(11):1392-8
pubmed: 24076601
Ethn Dis. 2010 Winter;20(1 Suppl 1):S1-96-100
pubmed: 20521394
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Cancer. 2003 Nov 15;98(10):2088-90
pubmed: 14601076
Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50
pubmed: 9184779
Genome Biol. 2016 Jan 26;17:10
pubmed: 26813233
J Urol. 1999 Jan;161(1):304-8
pubmed: 10037428
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Br J Cancer. 2009 Mar 24;100(6):888-93
pubmed: 19293807
J Urol. 2019 Aug;202(2):247-255
pubmed: 31107158
Prostate. 2011 Jun 1;71(8):857-71
pubmed: 21456068
EMBO J. 2013 Jun 12;32(12):1665-80
pubmed: 23644382
Cancer Rep (Hoboken). 2019 Apr;2(2):e1153
pubmed: 32721098
J Cell Mol Med. 2008 Dec;12(6B):2790-8
pubmed: 18266956
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7
pubmed: 23515145
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Cancer Res. 2014 Mar 15;74(6):1651-60
pubmed: 24473064
Oncogene. 2008 Jan 10;27(3):253-63
pubmed: 17637754
Prostate. 2003 May 15;55(3):199-205
pubmed: 12692786
Lancet. 1992 Apr 11;339(8798):887-9
pubmed: 1348296
Oncogene. 2020 May;39(21):4299-4311
pubmed: 32300177
Int J Biol Sci. 2014 Jun 05;10(6):643-51
pubmed: 24948877
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1765-71
pubmed: 15533905
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Eur Urol. 2017 May;71(5):697-700
pubmed: 27477529
Nat Commun. 2014 Nov 21;5:5383
pubmed: 25415230
Cancer Metastasis Rev. 2012 Dec;31(3-4):615-20
pubmed: 22684368
J Carcinog. 2012;11:4
pubmed: 22438770
Science. 1997 Aug 15;277(5328):955-9
pubmed: 9252327
Science. 1996 Nov 22;274(5291):1371-4
pubmed: 8910276
Epigenetics. 2015;10(4):319-28
pubmed: 25864488
Nat Genet. 2006 Jun;38(6):652-8
pubmed: 16682969
Eur Urol. 2017 Mar;71(3):417-425
pubmed: 27590317
Prostate. 2008 Sep 1;68(12):1341-53
pubmed: 18512729
Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1520-8
pubmed: 23833122
PLoS One. 2013 Sep 23;8(9):e74688
pubmed: 24086362
Nat Genet. 2012 May 20;44(6):685-9
pubmed: 22610119
PLoS One. 2017 Oct 5;12(10):e0183122
pubmed: 28981528
Int J Cancer. 2005 Aug 20;116(2):174-81
pubmed: 15800905
Curr Drug Targets. 2013 Sep;14(10):1175-84
pubmed: 23834145
J Urban Health. 2006 Nov;83(6):1041-62
pubmed: 17031568
Endocr Relat Cancer. 2011 Mar 09;18(2):245-55
pubmed: 21317204
Am J Pathol. 2014 Oct;184(10):2598-607
pubmed: 25088980
J Invest Dermatol. 2011 Dec;131(12):2497-500
pubmed: 21833010
Prostate. 2010 Nov 1;70(15):1716-27
pubmed: 20564318